Hope in a pill? ebola drug favipiravir tested in guinea

NCT ID NCT02329054

Completed Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested the antiviral drug favipiravir in 126 people with Ebola in Guinea. The goal was to see if it could reduce deaths. Participants received high doses of the drug by mouth for up to 10 days. The study aimed to find a practical treatment for Ebola, which currently has no specific cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: favipiravir (an antiviral drug)
What this could lead to: If successful, this could provide a simple oral treatment to lower death rates from Ebola, especially in outbreak settings.
What could go wrong: This is a small Phase 2 trial with 126 people, so results may not be definitive. The drug may not work as well in humans as in lab studies, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBOLA VIRUS DISEASE

Contacts and locations

Locations

ALIMA Ebola care center

Nzérékoré, Guinea
French Red Cross Ebola care center

Macenta, Guinea
MSF Ebola treatment centre

Gueckedou, Guinea
The caregivers treatment center

Conakry, Guinea

More trials for these conditions

Other studies related to the condition(s) this trial covers.